Northland Securities reiterated coverage of Nabriva Therapeutics with a rating of Outperform and set a new price target of $6.00 from $9.00 previously

SC 13G/A - Nabriva Therapeutics plc (0001641640) (Subject)

SC 13G - Nabriva Therapeutics plc (0001641640) (Subject)

SC 13G/A - Nabriva Therapeutics plc (0001641640) (Subject)

15-12G - Nabriva Therapeutics plc (0001641640) (Filer)

EFFECT - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

POS AM - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

3 - Nabriva Therapeutics plc (0001641640) (Issuer)

3 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

4 - Nabriva Therapeutics plc (0001641640) (Issuer)

Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l

-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company's operations. As previously disclosed, the Company engaged Torreya Capital to facilitate the exploration of a range of strategic options, including potential in-licensing or out-licensing of commercial stage assets. While the Company continues to work with Torreya Capital

- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF). "We are excited to share positive topline

- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options. Nabriva also issued financial results for the t

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 833-634-2311 for domestic participants and 412-902-4177 for international p

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. At the Annual General Meeting of Shareholders on August 11, 2022, Nabriva Therapeutics' shareholders approved, subject to and conditional upon the Board of Directors of Nabriva Therapeutics determining,

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also host investor meetings September 12-14, 2022. About Nabriva Therapeutics plc Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat seri

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the completion of patient enrollment in its Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF). "We are happy to announce enrollment has been completed in this important study to evaluate the potential of XENLETA in the management of bacterial infections in patients with cystic fibrosis," said Christine Guico-Pabia, M.D., MB

-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2022 and provided a corporate update. "We continued to accelerate our commercial growth through improved sales execution in the second quarter of 2022. We are seeing significant early success from our increased focus on SIVEXTRO

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. To participate in the conference call, please dial 833-634-2311 for domestic participants and 412-902-4177 for internation

Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr. Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021. "We are very pleased to have Christine join our senior leadership team. Christine brings a well-rounded profile to the CMO role, with extensive experience across several therapeutic areas from clinical development through to the post-marketing support of multiple commercial stage products over the course of h

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief Financial Officer (CFO), effective close of business March 12, 2021. Mr. Dolan will replace current CFO Gary Sender, who is retiring from Nabriva. Mr. Sender will serve as a consultant for Nabriva at least through the remainder of 2021 to support Mr. Dolan’s transition into the CFO role. “We are very pleased to have Dan join our leadership team. Dan is a seasoned business le

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial Officer (CFO), effective as of March 12, 2021. Mr. Sender has agreed to serve as a consultant for Nabriva on an ongoing basis following his retirement to ensure business continuity. Mr. Sender informed Nabriva that he plans to focus on his three public company Board roles and providing financial advisory services. A search has been initiated to identify a new CFO. “We th

- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options. Nabriva also issued financial results for the t

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 833-634-2311 for domestic participants and 412-902-4177 for international p

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. At the Annual General Meeting of Shareholders on August 11, 2022, Nabriva Therapeutics' shareholders approved, subject to and conditional upon the Board of Directors of Nabriva Therapeutics determining,

-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2022 and provided a corporate update. "We continued to accelerate our commercial growth through improved sales execution in the second quarter of 2022. We are seeing significant early success from our increased focus on SIVEXTRO

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. To participate in the conference call, please dial 833-634-2311 for domestic participants and 412-902-4177 for internation

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2022 and provided a corporate update. "We continued to execute on our near-term strategy in the first quarter

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, May 5, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 800-579-2543 for domestic participants and 203-518-9708 for international particip

-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, March 29, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and year ended December 31, 2021 and provided a corporate update. "We saw continued progress in our commercial business during the fourth quarter of 2021, w

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2021 financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, March 29, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 fo

-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended September 30, 2021 and provided a corporate update. "We saw our commercial business continue to gain momentum in the third quarter, with total

-NT 10Q

-8-K

Companies That Fell Through 52-Week Lows Monday During Monday's morning trading, 14 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: L3Harris Technologies (NYSE:LHX) was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to hit a new 52-week low was Nabriva Therapeutics (NASDAQ:NBRV). Cutera (NASDAQ:CUTR) shares traded down 23.86% to reach its 52-week low, making it the biggest loser. Nabriva Therapeutics (NASDAQ:NBRV)'s stock made the biggest reversal, trading up 0.77% shortly after dropping to a new 52-week low. Here is a list of stocks that set new 52-week lows on Monday: L3Harris Technologies (

Gainers Swvl Holdings Corp. (NASDAQ:SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. Spruce Biosciences, Inc. (NASDAQ:SPRB) shares jumped 100.8% to $2.51. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan. MedAvail Holdings, Inc. (NASDAQ:MDVL) gained 54% to $0.4745. MedAvail Holdings, during November, posted a Q3 loss of $0.15 per share. CytomX Therapeutics, Inc. (NASDAQ:CTMX) climbed 46.4% to $2.6198. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics. Zomedica Corp. (NYSE:ZO

  During Friday's trading, 71 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Amazon.com (NASDAQ:AMZN). The smallest company by market cap to set a new 52-week low was Nabriva Therapeutics (NASDAQ:NBRV). NextPlay Technologies (NASDAQ:NXTP) saw the most significant move of the companies, as shares traded down 1445.45% to reach its new 52-week low. MasterBrand (NYSE:MBC) shares actually gained 0.07%, rebounding after it reached its 52-week low. Here is a list of stocks that set new 52-week lows on Friday: Amazon.com (NASDAQ:AMZN) shares fell to $81.44 on Friday, setting a new 52-week low w

-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-   -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company's operations. As previously disclosed, the Company engaged Torreya Capital to facilitate the exploration of a range of strategic options, including potential in-licensing or out-licensing of commercial stage assets. While the Company continues to work with Torreya Capital

  Friday's session saw 75 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: Blackstone Mortgage Trust (NYSE:BXMT) was the largest company by market cap to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Mobilicom (NASDAQ:MOB). NanoVibronix (NASDAQ:NAOV) made the largest move down on the session, with shares plummeting 12.14% to reach its 52-week low. Autoscope Technologies (NASDAQ:AATC)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. The following stocks created new 52-week lows on Friday: Blackstone Mortgage Trust (NYSE:BXMT) shares moved down 1.91% on Friday to hit a new

  On Tuesday, 89 companies set new 52-week lows. Noteable 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Lucid Gr (NASDAQ:LCID). Infobird Co (NASDAQ:IFBD) was the smallest, in terms of market cap, to set a new 52-week low. CNS Pharmaceuticals (NASDAQ:CNSP) saw the most pronounced move, as shares traded down 2455.54% to hit its new 52-week low. Lilium (NASDAQ:LILM)'s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low. On Tuesday, the following stocks broke to new 52-week lows: Lucid Gr (NASDAQ:LCID) shares reached a new 52-week low of $9.80 on Tuesday morning, moving down 0.3%. Credit Suisse Group (NYSE:C

Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF). “We are excited to share positive topline results from this important study of XENLETA in patients with CF,” said Christine Guico-Pabia, M.D., MBA, MPH, Nabriva’s Chief Medical Officer. “The data indicate that the PK of XENLETA in CF patients is consistent with that observed in previous single-dose he